CYP2C19 and Hypoglycemia: However, when stratified by the CYP2C19 phenotypes, the co-treatment with PPIs was associated with severe hypoglycemia only in CYP2C19*2 non-carriers [OR = 2.34 (1.02–5.37), p = 0.044] (Figure 5).